# Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

> **NCT00570258** · PHASE2 · TERMINATED · sponsor: **University of Arkansas** · enrollment: 27 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** erlotinib
- **DRUG:** Fulvestrant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00570258
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2010-12
- **Final completion:** 2017-12
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** FDA approved higher dose of study drug. Dose used in protocol lower than SOC - enrollment stopped, those on treatment were given option to opt out.
- **Last updated:** 2021-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00570258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00570258, "Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00570258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*